Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients

Liver International

Volumn 32, Issue 6, 2012, Pages 928-936

  Kao, Jung Ta ^a,b,c   Lai, Hsueh Chou ^c   Tsai, Shu Mei ^d   Lin, Pei Chao ^e   Chuang, Po Heng ^c   Yu, Cheng Ju ^c   Cheng, Ken Sheng ^c   Su, Wen Pang ^c   Hsu, Ping Ning ^f   Peng, Cheng Yuan ^a,c   Wu, Yi Ying ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cytokines; Hepatitis B virus infected patients; Hepatocellular carcinoma; Interleukin 27 interleukin 6; Liver cirrhosis

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; INTERLEUKIN 27; INTERLEUKIN 6;

ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HEPATITIS B; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKIN-6; INTERLEUKINS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TAIWAN; YOUNG ADULT;

EID: 84862806473     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02742.x     Document Type: Article

References (41)

1. Goldstein ST, Zhou F, Hadler SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-39.
2. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
3. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
4. Yin J, Xie J, Liu S, et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carriers state to hepatocellular carcinoma. Am J Gastro enterol 2011; 106: 81-92.
5. Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol 2006; 3: 97-106.
6. Hui CK, Lau GK. Immune system and hepatitis B virus infection. J Clin Virol 2005; 34(Suppl 1): S44-8.
7. Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Microbiol 2000; 3: 387-92.
8. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003; 19: 641-4.
9. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naïve CD4(+) T cells. Immunity 2002; 16: 779-90.
10. Devergne O, Hummel M, Koeppen H, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996; 70: 1143-53.
11. Bender H, Wiesinger MY, Nordhoff C, et al. Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology 2009; 50: 585-91.
12. Schoenherr C, Weiskirchen R, Haan S. Interleukin-27 acts on hepatic stellate cells and induces signal transducer and activator of transcription 1-dependent responses. Cell Commun Signal 2010; 19: 8-19.
13. Artis D, Villarino A, Silverman M, et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol 2004; 173: 5626-34.
14. Villarino AV III, Larkin J, Saris CJ, et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol 2005; 174: 7684-91.
15. Larousserie F, Charlot P, Bardel E, et al. Differential effects of IL-27 on human B cell subsets. J Immunol 2006; 176: 5890-7.
16. Pearl JE, Khader SA, Solache A, et al. IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J Immunol 2004; 173: 7490-6.
17. Yamanaka A, Hamano S, Miyazaki Y, et al. Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis. J Immunol 2004; 172: 3590-6.
18. Batten M, Li J, Yi S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006; 7: 929-36.
19. Stumhofer JS, Laurence A, Wilson EH, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006; 7: 937-45.
20. Miyazaki Y, Inoue H, Matsumura M, et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol 2005; 175: 2401-7.
21. Shimizu S, Sugiyama N, Masutani K, et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 2005; 175: 7185-92.
22. Neufert C, Becker C, Wirtz S, et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol 2007; 37: 1809-16.
23. Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol 2004; 173: 715-20.
24. Villarino AV, Hunter CA. Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res Ther 2004; 6: 225-33.
25. Hisada M, Kamiya S, Fujita K, et al. Potent antitumor activity of interleukin-27. Cancer Res 2004; 64: 1152-6.
26. Shimizu M, Shimamura M, Owaki T, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006; 176: 7317-24.
27. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-83.
28. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-4.
29. Song le H, Binh VQ, Duy DN, et al. Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. J Clin Virol 2003; 28: 93-103.
30. Hsia CY, Huo TI, Chiang SY, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007; 33: 208-12.
31. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-19.
32. Batten M, Ghilardi N. The biology and therapeutic potential of interleukin 27. J Mol Med 2007; 85: 661-72.
33. Zhu C, Zhang R, Liu L, et al. Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro. Clin Immunol 2009; 131: 92-7.
34. Takeda A, Hamano S, Yamanaka A, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003; 170: 4886-90.
35. Tangkijvanich P, Vimolket T, Theamboonlers A, et al. Serum interleukin-6 and interferon-gamma levels in patients with hepatitis B-associated chronic liver disease. Asian Pac J Allergy Immunol 2000; 18: 109.
36. Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990; 87: 6599-603.
37. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007; 85: 16-23.
38. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
39. Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-83.
40. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
41. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose ranging study of the efficacy and tolerability of entecavir in lamivudine refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-209.